Tasly Pharmaceutical Group Co., Ltd.

Tasly Pharmaceutical Group Co., Ltd. is one of China's most scientifically sophisticated modern traditional Chinese medicine enterprises, distinguished by its systematic application of contemporary pharmaceutical science to the standardization and international regulatory registration of TCM formulations. The company achieved revenue of RMB 8.24 billion in 2025 with net profit of RMB 1.10 billion and total assets of RMB 15.34 billion. Tasly operates manufacturing facilities built to FDA cGMP standards, an exceptionally rare level of international quality certification among TCM manufacturers, and maintains an extensive pipeline of 98 active pharmaceutical development programs spanning cardiovascular, oncology, and neurological indications. The company's core technological competencies include proprietary active ingredient extraction and drop pill formulation technologies enabling precise dosage standardization. In a landmark 2025 transaction, China Resources Sanjiu acquired a controlling equity stake in Tasly, integrating the company into the vast CR pharmaceutical ecosystem and creating significant synergies in R&D, manufacturing, and distribution capabilities.

Core Business

Tasly Pharmaceutical Group Co., Ltd. has established itself as one of China's most scientifically sophisticated and internationally oriented modern traditional Chinese medicine enterprises, distinguished by its systematic application of contemporary pharmaceutical science methodologies to the standardization, clinical validation, and international regulatory registration of traditional Chinese medicine formulations. In fiscal year 2025, the company achieved consolidated revenue of RMB 8.24 billion, while net profit attributable to shareholders reached RMB 1.10 billion, with total consolidated assets amounting to RMB 15.34 billion, reflecting a fundamentally sound financial position despite the transitional challenges associated with the company's evolving ownership structure and strategic repositioning. Tasly's pharmaceutical manufacturing operations are conducted at modern production facilities that have been purpose-built to comply with the United States Food and Drug Administration's current Good Manufacturing Practice standards, representing a level of international pharmaceutical manufacturing quality certification that is exceptionally rare among traditional Chinese medicine manufacturers and that positions Tasly uniquely for regulatory product registrations in developed-country pharmaceutical markets. The company's research and development pipeline encompasses an impressive 98 active pharmaceutical development programs spanning cardiovascular disease, cerebrovascular disorders, digestive system conditions, metabolic diseases, oncology supportive care, and neurological disorders, representing one of the most extensive and scientifically rigorous research portfolios in the Chinese traditional medicine industry. Tasly's core technological competencies center on its proprietary mastery of traditional Chinese medicine active ingredient extraction and quantification technologies, including advanced drop pill formulation techniques that enable precise dosage standardization, improved bioavailability, and pharmaceutical presentation formats that are familiar and acceptable to Western-trained physicians and regulatory authorities. The company employs a substantial workforce of pharmaceutical scientists, clinical research professionals, manufacturing technicians, and commercial operations staff distributed across its research centers, manufacturing facilities, and regional sales offices throughout China. In a strategically transformative development completed during fiscal year 2025, China Resources Sanjiu Medical and Pharmaceutical Co., Ltd. successfully acquired a controlling equity stake in Tasly, integrating the company into the vast China Resources pharmaceutical ecosystem and creating significant potential synergies in research and development, manufacturing, distribution, and brand marketing capabilities.

Global Presence

Tasly Pharmaceutical's international business operations and global regulatory achievements represent arguably the most significant international footprint of any Chinese traditional medicine enterprise, anchored by the company's pioneering pursuit of United States Food and Drug Administration new drug application approval for a traditional Chinese medicine formulation, a regulatory milestone that no other Chinese traditional medicine company has achieved. The company's principal international pharmaceutical asset is its flagship cardiovascular formulation, Compound Danshen Dripping Pill, which has successfully completed multiple phases of clinical investigation under FDA oversight and has progressed further through the United States pharmaceutical regulatory approval process than any other traditional Chinese medicine product in history, generating an extensive clinical data package that supports regulatory submissions in multiple international markets. Tasly has established pharmaceutical product registrations and commercial distribution partnerships in a substantial number of countries across Asia, Africa, Eastern Europe, and the Commonwealth of Independent States, with a particular concentration of market presence in Southeast Asian countries where traditional Chinese medicine enjoys established regulatory recognition and consumer acceptance. The company operates internationally certified manufacturing facilities that have been inspected and approved by regulatory authorities from multiple countries, providing the quality assurance infrastructure required to supply pharmaceutical products to markets with rigorous regulatory standards. Tasly has cultivated extensive international research collaboration relationships with academic medical centers, contract research organizations, and clinical research professionals in the United States, Europe, Australia, and Asia, building a global clinical research network that supports the company's ambitious international regulatory submission strategy. The company participates actively in international pharmaceutical industry conferences, regulatory harmonization forums, and traditional medicine standardization initiatives organized through the World Health Organization, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and various bilateral pharmaceutical regulatory cooperation agreements. Through the strategic integration into the China Resources Sanjiu ecosystem, Tasly gains access to substantially expanded international distribution channels, regulatory affairs expertise, and financial resources that should accelerate and amplify the company's existing international growth trajectory over the medium to long term.

Key Strengths

Tasly's most strategically valuable and competitively distinctive asset is its unparalleled progress in pursuing formal pharmaceutical regulatory approval for a traditional Chinese medicine formulation from the United States Food and Drug Administration, an achievement that required decades of sustained investment in basic pharmacological research, clinical trial execution, manufacturing quality system development, and regulatory dossier preparation at a level of scientific rigor that no other Chinese traditional medicine enterprise has matched. This FDA clinical development program has generated a comprehensive package of preclinical pharmacology data, clinical safety information, and clinical efficacy evidence that provides a scientific credibility foundation for the company's products that far exceeds the evidence base available for any competing traditional Chinese medicine formulation and that supports product differentiation and premium pricing in both international and domestic markets. The company's manufacturing facilities, purpose-built and certified to comply with FDA current Good Manufacturing Practice standards, represent pharmaceutical production quality infrastructure that enables regulatory product registrations in sophisticated international markets that are fundamentally inaccessible to traditional Chinese medicine manufacturers operating at lower quality standards. Tasly's extensive research and development pipeline comprising 98 active development programs provides substantial product portfolio depth and future revenue growth optionality, with clinical-stage assets across multiple high-value therapeutic categories including cardiovascular disease, oncology, and neurology that address large and growing global patient populations. The company's proprietary expertise in active pharmaceutical ingredient identification, extraction optimization, and quantification technologies for complex traditional Chinese medicine formulations represents specialized scientific capabilities that are difficult to replicate and that provide a foundation for continued product innovation and patent-protected competitive differentiation. The strategic acquisition of controlling equity in Tasly by China Resources Sanjiu, one of China's most powerful pharmaceutical enterprises with exceptional brand marketing capabilities and vast distribution network reach, creates significant potential for revenue synergies, cost efficiencies, and accelerated commercialization of Tasly's research pipeline products. The company's strong balance sheet position with total assets of RMB 15.34 billion provides financial stability and investment capacity during the ownership transition period, while China Resources Sanjiu's substantial financial resources and AAA credit rating provide additional capital support for accelerated research investment and international market expansion initiatives. Tasly's accumulated experience and institutional knowledge in navigating complex international pharmaceutical regulatory processes represents an intangible but highly valuable organizational capability that provides sustainable competitive advantage in the progressively globalizing traditional Chinese medicine industry. VerityRank Score of 85/100